Media

June 15th, 2020  | Press Release

Arranta Bio Announces Addition of Shailesh Maingi to its Board as an Independent Director

 Arranta Bio (“Arranta”), the leading microbiome contract development and manufacturing organization (CDMO), today announced the addition of Shailesh Maingi to Arranta’s board as an Independent Director. Shailesh Maingi is the founder and CEO of Kineticos Life Sciences, a boutique advisory focused on strategy, licensing and commercial product launch that he established in 2007. In 2019 he founded the…

Read More

May 29th, 2020  | Press Release

Arranta Bio Announces Completion of its Microbiome Process Development Lab Expansion and Commitment to Additional Early Clinical GMP Capacity

Arranta Bio (“Arranta”), the leading microbiome contract development and manufacturing organization (CDMO), today announced the completion of its microbiome process development lab expansion project and a commitment to add additional early- clinical GMP capacity at its Center of Excellence for Microbiome Process Development and Early Clinical Supply. Arranta has completed the expansion of purpose-built microbiome…

Read More

April 2nd, 2020  | article

Aaron Cowley Talks Process Development of LBPs

As an inorganic chemistry student at Benedictine College, Aaron Cowley, Arranta Bio’s Chief Scientific Officer, didn’t expect to someday lead a biotechnology company focused on the process development of LBPs. Even as a doctoral and post-doctoral student, Aaron’s passion was the potential therapeutic nature of enzymes, which led him to start Captozyme, a CDMO supporting…

Read More

January 30th, 2020  | Press Release

Arranta Bio announces key leadership additions of Chief Operations Officer and SVP of Business Development as it commits to a $100M investment in building end-to-end microbiome capacity

Watertown, MA – January 28, 2020: Arranta Bio (“Arranta”), the leading microbiome contract development and manufacturing organization (CDMO), announced today the strengthening of its senior leadership team with the addition of David Stevens as Chief Operations Officer and Jason Rahal as Senior Vice President of Business Development. Arranta has committed $100M to build end-to-end capacity…

Read More

November 13th, 2019  | Press Release

Arranta Bio announces the acquisition of Captozyme™, creating a Center of Excellence for microbiome development and clinical supply

Watertown, MA – November [13], 2019: Arranta Bio (“Arranta”) announced today the acquisition of Captozyme™, and with it the establishment of Arranta’s Center of Excellence for process and analytical development and early clinical supply for microbiome clients with the transfer of the Captozyme team and facilities in Gainesville, FL to Arranta.  Formed in 2009, Captozyme has…

Read More

October 29th, 2019  | Press Release

Arranta Bio announces $82M in new funding, and a strategic partnership with Thermo Fisher Scientific

Watertown, MA – October 29, 2019: Arranta Bio (“Arranta”) announced today the completion of an $82 million funding round and a strategic partnership with Thermo Fisher Scientific.  Formed in May 2019, Arranta’s goal is to be the best-in-class microbiome contract development and manufacturing organization (CDMO). The business provides live biopharmaceutical products (LBPs) for microbiome pioneers by…

Read More
At Arranta Bio, we embrace the diversity of backgrounds that make up our company and our community. Each employee at Arranta has the opportunity to grow their career and care for their families irrespective of race or ethnicity. Arranta Bio is an Equal Opportunity Employer. We are committed to addressing barriers that exist for minorities and welcome diverse employees who share our core values.
+